COVID-19 among fit patients with CLL treated with venetoclax-based combinations

  1. Fürstenau, Moritz ORCID logo
  2. Langerbeins, Petra
  3. De Silva, Nisha
  4. Fink, Anna Maria
  5. Robrecht, Sandra
  6. von Tresckow, Julia
  7. Simon, Florian
  8. Hohloch, Karin
  9. Droogendijk, Jolanda
  10. van der Klift, Marjolein
  11. van der Spek, Ellen
  12. Illmer, Thomas
  13. Schöttker, Björn
  14. Fischer, Kirsten
  15. Wendtner, Clemens-Martin ORCID logo
  16. Tausch, Eugen
  17. Stilgenbauer, Stephan
  18. Niemann, Carsten ORCID logo
  19. Gregor, Michael
  20. Kater, Arnon P.
  21. Hallek, Michael
  22. Eichhorst, Barbara

Download
s41375-020-0941-7.pdf 436,11KB
WeightNameValue
1000 Titel
  • COVID-19 among fit patients with CLL treated with venetoclax-based combinations
1000 Autor/in
  1. Fürstenau, Moritz |
  2. Langerbeins, Petra |
  3. De Silva, Nisha |
  4. Fink, Anna Maria |
  5. Robrecht, Sandra |
  6. von Tresckow, Julia |
  7. Simon, Florian |
  8. Hohloch, Karin |
  9. Droogendijk, Jolanda |
  10. van der Klift, Marjolein |
  11. van der Spek, Ellen |
  12. Illmer, Thomas |
  13. Schöttker, Björn |
  14. Fischer, Kirsten |
  15. Wendtner, Clemens-Martin |
  16. Tausch, Eugen |
  17. Stilgenbauer, Stephan |
  18. Niemann, Carsten |
  19. Gregor, Michael |
  20. Kater, Arnon P. |
  21. Hallek, Michael |
  22. Eichhorst, Barbara |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-29
1000 Erschienen in
1000 Quellenangabe
  • 34(8):2225-2229
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-020-0941-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323604/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted to patients up to 65 years of age. Prospective phase III trial data in the era of novel agents for patients up to 70 years of age are not available. The GMMG-MM5 trial included 601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n = 353), 61-65 years (S2, n = 107) and 66-70 years (S3, n = 141). Treatment consisted of a bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide. Adherence to treatment was similar among patients of the three age groups. Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001). With respect to progression-free survival (log-rank p = 0.73), overall survival (log-rank p = 0.54) as well as time-to-progression (Gray's p = 0.83) and non-relapse mortality (Gray's p = 0.25), no differences were found between the three age groups. Our results imply that an intensive upfront therapy with a bortezomib-containing IT, MEL200/ASCT, lenalidomide consolidation, and maintenance should be applied to transplant-eligible MM patients up to 70 years of age.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Letter
lokal Chronic lymphocytic leukaemia
lokal Aged [MeSH]
lokal Bridged Bicyclo Compounds, Heterocyclic/administration
lokal Pneumonia, Viral/transmission [MeSH]
lokal Antibodies, Monoclonal, Humanized/administration
lokal Rituximab/administration
lokal Leukemia, Lymphocytic, Chronic, B-Cell/pathology [MeSH]
lokal Male [MeSH]
lokal Pneumonia, Viral/virology [MeSH]
lokal COVID-19 [MeSH]
lokal Leukemia, Lymphocytic, Chronic, B-Cell/virology [MeSH]
lokal Targeted therapies
lokal SARS-CoV-2 [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Coronavirus Infections/diagnosis [MeSH]
lokal Humans [MeSH]
lokal Infectious diseases
lokal Pyrimidines/administration
lokal Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy [MeSH]
lokal Middle Aged [MeSH]
lokal Betacoronavirus/isolation
lokal Sulfonamides/administration
lokal Pyrazoles/administration
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Randomized controlled trials
lokal Pandemics [MeSH]
lokal Coronavirus Infections/virology [MeSH]
lokal Coronavirus Infections/transmission [MeSH]
lokal Prognosis [MeSH]
lokal Pneumonia, Viral/diagnosis [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-6593-0140|https://frl.publisso.de/adhoc/uri/TGFuZ2VyYmVpbnMsIFBldHJh|https://frl.publisso.de/adhoc/uri/RGUgU2lsdmEsIE5pc2hh|https://frl.publisso.de/adhoc/uri/RmluaywgQW5uYSBNYXJpYQ==|https://frl.publisso.de/adhoc/uri/Um9icmVjaHQsIFNhbmRyYQ==|https://frl.publisso.de/adhoc/uri/dm9uIFRyZXNja293LCBKdWxpYQ==|https://frl.publisso.de/adhoc/uri/U2ltb24sIEZsb3JpYW4=|https://frl.publisso.de/adhoc/uri/SG9obG9jaCwgS2FyaW4=|https://frl.publisso.de/adhoc/uri/RHJvb2dlbmRpamssIEpvbGFuZGE=|https://frl.publisso.de/adhoc/uri/dmFuIGRlciBLbGlmdCwgTWFyam9sZWlu|https://frl.publisso.de/adhoc/uri/dmFuIGRlciBTcGVrLCBFbGxlbg==|https://frl.publisso.de/adhoc/uri/SWxsbWVyLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/U2Now7Z0dGtlciwgQmrDtnJu|https://frl.publisso.de/adhoc/uri/RmlzY2hlciwgS2lyc3Rlbg==|https://orcid.org/0000-0003-2866-2260|https://frl.publisso.de/adhoc/uri/VGF1c2NoLCBFdWdlbg==|https://frl.publisso.de/adhoc/uri/U3RpbGdlbmJhdWVyLCBTdGVwaGFu|https://orcid.org/0000-0001-9880-5242|https://frl.publisso.de/adhoc/uri/R3JlZ29yLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/S2F0ZXIsIEFybm9uIFAu|https://frl.publisso.de/adhoc/uri/SGFsbGVrLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/RWljaGhvcnN0LCBCYXJiYXJh
1000 Hinweis
  • DeepGreen-ID: 7d5e3c968327410da0387f1feddeccf4 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6471066.rdf
1000 Erstellt am 2023-11-18T10:41:23.911+0100
1000 Erstellt von 322
1000 beschreibt frl:6471066
1000 Zuletzt bearbeitet Fri Dec 01 13:36:52 CET 2023
1000 Objekt bearb. Fri Dec 01 13:36:52 CET 2023
1000 Vgl. frl:6471066
1000 Oai Id
  1. oai:frl.publisso.de:frl:6471066 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source